Exelixis, Inc. Reports Positive Phase 1 Data For PI3K/mTOR Inhibitor XL765 at EORTC-NCI-AACR Symposium

GENEVA--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL765, a novel small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The trial is being carried out in patients with metastatic or unresectable solid tumors for which known effective measures do not exist or are no longer effective. Dr. Ben Markman, Medical Oncologist, Vall D’Hebron University Hospital, Barcelona, Spain, and a lead investigator in the trial, presented the data in a poster session (Abstract #216) at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is being held October 21-24 in Geneva, Switzerland. The poster will be available today on the Exelixis web site.